 |
 |
 |
| Technology | Programs | Pipeline | Collaborations | About Us | Contact Us |
 |
| |
Pipeline
Medisyn is committed to creating superior products for important medical needs. Using our platform technology, we have rapidly advanced a broad portfolio of preclinical candidates that target major therapeutic categories including cancer, infectious disease, pain, sexual health and inflammation.
Key programs in Medisyn's Pipeline:
| Pharmaceutical |
Oncology
|
 |
Non-small Cell Lung Cancer
PKC Inhibition
RAS Pathway
|
|
Pancreatic Cancer
RAS Pathway |
|
Malignant Melanoma
RTKI |
|
| |
|
Infectious Disease
|
|
HIV/AIDS
Protease Inhibition |
|
| MRSA |
|
| Tuberculosis |
|
| |
|
Neuropathic Pain
|
|
| GABA-mimetics |
 |
MD Biosciences |
|
| GABA Receptor Agonists |
|
MD Biosciences |
|
| |
|
Alzheimer's Disease
|
|
Selective Aβ1-40 and Aβ1-42
lowering agents |
|
MSSM |
|
| Anti-aggregation agents |
|
MSSM |
|
| |
|
Inflammation
|
|
| Non-steroidal Anti-inflammatory |
|
| |
|
| Nutraceutical |
Acute Radiation Syndrome (ARS)
|
|
Radioprotectants
|
|
Humanetics |
|
Radiotherapeutics
|
|
Humanetics |
|
| |
|
Satiety
|
|
| Serotonin inhibition |
|
| Dopamine Inhibition |
|
| Norepinephrine |
|
| |
|
Sexual Health
|
|
| Erectile Dysfunction |
|
| Inhibited Sexual Disorder |
|
| Premature Ejaculation |
|
| |
|
|
|
| |
|
|
|
|
|
|
 |
